Evidence map›Paper›PMID 35441233›Full record

ArticleBrain : a journal of neurology2022

Somatic variants in diverse genes leads to a spectrum of focal cortical malformations.

Dulcie Lai, Meethila Gade, Edward Yang, Hyun Yong Koh, Jinfeng Lu, Nicole M Walley, Anne F Buckley, Tristan T Sands, Cigdem I Akman, Mohamad A Mikati and 15 more

Open access · bronzeAbstract read
In one paragraph

Article in Brain : a journal of neurology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 55 papers.

0numbers the graph read from it
0cells of the map it votes in
55citing papers in PubMed
13.1field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

55 citing papers in PubMed, 75 citations in OpenAlex.

  1. Ras-MAPK somatic variants in mesial temporal lobe epilepsy.Current opinion in genetics & development · 2026
    Review
  2. Genetic Diagnosis in Epilepsy: Implications for Clinical Management.Current neurology and neuroscience reports · 2026
    Review
  3. Review
  4. Deep tissue sequencing improves genetic diagnostic yield in focal cortical dysplasia.Progress in neuro-psychopharmacology & biological psychiatry · 2026
    Article
  5. Drug resistant epilepsy driven byEpilepsy & behavior reports · 2026
    Article
  6. CRL4EMBO reports · 2026
    Article
  7. Article
  8. Disease insights from brain somatic mosaicism.Experimental & molecular medicine · 2026
    Review
  9. Article
  10. Disrupted O-GalNAc glycosylation as a mechanism and biomarker ofbioRxiv : the preprint server for biology · 2026
    Article
  11. Article
  12. Review
  13. Early death and neuronal abnormalities inbioRxiv : the preprint server for biology · 2025
    Article
  14. Deep tissue sequencing improves genetic diagnostic yield in focal cortical dysplasia.medRxiv : the preprint server for health sciences · 2025
    Article
  15. Article
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

25 authors at 12 institutions in 1 country.

Dulcie LaiDivision of Pharmacology and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Meethila GadeDivision of Pharmacology and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Edward YangDepartment of Radiology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.ORCID 0000-0002-9912-4163
Hyun Yong KohDivision of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Boston, MA 02115, USA.
Jinfeng LuDivision of Pharmacology and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Nicole M WalleyDivision of Medical Genetics, Department of Pediatrics, Duke University School of Medicine, Durham, NC 27710, USA.
Anne F BuckleyDepartment of Pathology, Duke University Medical Center, Durham, NC 27710, USA.
Tristan T SandsInstitute for Genomic Medicine, Columbia University Medical Center, New York, NY 10032, USA.
Cigdem I AkmanDepartment of Neurology, Columbia University Medical Center, New York, NY 10032, USA.
Mohamad A MikatiDepartment of Neurobiology, Duke University, Durham, NC 27708, USA.ORCID 0000-0003-0363-8715
Guy M McKhannDepartment of Neurosurgery, Columbia University, New York Presbyterian Hospital, New York, NY 10032, USA.ORCID 0000-0002-9695-3564
James E GoldmanDepartment of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.
Peter CanollDepartment of Pathology and Cell Biology, Columbia University, New York, NY 10032, USA.
Allyson L AlexanderDepartment of Neurosurgery, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Kristen L ParkDepartment of Pediatrics and Neurology, University of Colorado School of Medicine, Aurora, CO 80045, USA.
Gretchen K Von AllmenDepartment of Neurology, McGovern Medical School, Houston, TX 77030, USA.
Olga RodziyevskaDivision of Child Neurology, Department of Pediatrics, McGovern Medical School, Houston, TX 77030, USA.
Meenakshi B BhattacharjeeDepartment of Pathology and Laboratory Medicine, McGovern Medical School, Houston, TX 77030, USA.
Hart G W LidovDepartment of Pathology, Boston Children's Hospital, Harvard Medical School, Boston, MA 02115, USA.
Hannes VogelDepartment of Pathology, Stanford University, School of Medicine, Stanford, CA 94305, USA.
Gerald A GrantDepartment of Neurosurgery, Lucile Packard Children's Hospital at Stanford, School of Medicine, Stanford, CA 94305, USA.ORCID 0000-0002-2651-4603
Brenda E PorterDepartment of Neurology and Neurological Sciences, Stanford University, School of Medicine, Stanford, CA 94305, USA.
Annapurna H PoduriDivision of Epilepsy and Clinical Neurophysiology, Department of Neurology, Boston Children's Hospital, Boston, MA 02115, USA.
Peter B CrinoDepartment of Neurology, University of Maryland School of Medicine, Baltimore, MD 21201, USA.
Erin L HeinzenDivision of Pharmacology and Experimental Therapeutics, Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.ORCID 0000-0002-7268-8559
Boston Children's Hospital · USUniversity of North Carolina at Chapel Hill · USOffice of Multidisciplinary Activities · USColumbia University · USColumbia University Irving Medical Center · USDuke University · USStanford University · USUniversity of Colorado Denver · USDuke Medical Center · USLucile Packard Children's Hospital · USNewYork–Presbyterian Hospital · USUniversity of Maryland, Baltimore · US

Funding

Genetic Analysis and Manipulation Core (GAEC)P50HD105351 · NICHD · BOSTON CHILDREN'S HOSPITAL · PI SCOTT Loren POMEROY, MUSTAFA SAHIN · 2021 to 2026
$9.4M
Identification and molecular characterization of somatic mutations in MCDR01NS094596 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Peter B Crino, Erin L HEINZEN · 2016 to 2026
$5.9M
Defining disease mechanisms in SLC35A2 epilepsyR01NS115017 · NINDS · UNIV OF NORTH CAROLINA CHAPEL HILL · PI CRINO, PETER B, HEINZEN, ERIN L · 2020 to 2024
$3.7M
Somatic Mutation in Intractable Focal EpilepsyR01NS114122 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CRINO, PETER B, HEINZEN, ERIN L · 2020 to 2024
$3.3M
KPTN Loss and Megalencephaly: mTOR Activation as Therapeutic TargetR37NS125632 · NINDS · UNIVERSITY OF MARYLAND BALTIMORE · PI Peter B Crino · 2022 to 2026
$1.7M
Discovery of Novel Molecular Abnormalities Underlying Non-Lesional Focal EpilepsyR01NS089552 · NINDS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI CRINO, PETER B, WINAWER, MELODIE ROSE · 2014 to 2017
$1.4M
NICHD NIH HHS P50 HD105351NINDS NIH HHS R01 NS089552NINDS NIH HHS R01 NS094596NINDS NIH HHS R01 NS114122NINDS NIH HHS R01 NS115017NINDS NIH HHS R37 NS125632
6 · The paper itself

Abstract

Post-zygotically acquired genetic variants, or somatic variants, that arise during cortical development have emerged as important causes of focal epilepsies, particularly those due to malformations of cortical development. Pathogenic somatic variants have been identified in many genes within the PI3K-AKT-mTOR-signalling pathway in individuals with hemimegalencephaly and focal cortical dysplasia (type II), and more recently in SLC35A2 in individuals with focal cortical dysplasia (type I) or non-dysplastic epileptic cortex. Given the expanding role of somatic variants across different brain malformations, we sought to delineate the landscape of somatic variants in a large cohort of patients who underwent epilepsy surgery with hemimegalencephaly or focal cortical dysplasia. We evaluated samples from 123 children with hemimegalencephaly (n = 16), focal cortical dysplasia type I and related phenotypes (n = 48), focal cortical dysplasia type II (n = 44), or focal cortical dysplasia type III (n = 15). We performed high-depth exome sequencing in brain tissue-derived DNA from each case and identified somatic single nucleotide, indel and large copy number variants. In 75% of individuals with hemimegalencephaly and 29% with focal cortical dysplasia type II, we identified pathogenic variants in PI3K-AKT-mTOR pathway genes. Four of 48 cases with focal cortical dysplasia type I (8%) had a likely pathogenic variant in SLC35A2. While no other gene had multiple disease-causing somatic variants across the focal cortical dysplasia type I cohort, four individuals in this group had a single pathogenic or likely pathogenic somatic variant in CASK, KRAS, NF1 and NIPBL, genes previously associated with neurodevelopmental disorders. No rare pathogenic or likely pathogenic somatic variants in any neurological disease genes like those identified in the focal cortical dysplasia type I cohort were found in 63 neurologically normal controls (P = 0.017), suggesting a role for these novel variants. We also identified a somatic loss-of-function variant in the known epilepsy gene, PCDH19, present in a small number of alleles in the dysplastic tissue from a female patient with focal cortical dysplasia IIIa with hippocampal sclerosis. In contrast to focal cortical dysplasia type II, neither focal cortical dysplasia type I nor III had somatic variants in genes that converge on a unifying biological pathway, suggesting greater genetic heterogeneity compared to type II. Importantly, we demonstrate that focal cortical dysplasia types I, II and III are associated with somatic gene variants across a broad range of genes, many associated with epilepsy in clinical syndromes caused by germline variants, as well as including some not previously associated with radiographically evident cortical brain malformations.

Indexed as

EpilepsyHemimegalencephalyMalformations of Cortical DevelopmentCadherinsCell Cycle ProteinsFemaleHumansMalformations of Cortical Development, Group IMutationPhosphatidylinositol 3-KinasesProtocadherinsProto-Oncogene Proteins c-aktTOR Serine-Threonine KinasesCadherinsCell Cycle ProteinsNIPBL protein, humanPCDH19 protein, humanPhosphatidylinositol 3-KinasesProtocadherinsProto-Oncogene Proteins c-aktTOR Serine-Threonine Kinasesepilepsyexome sequencingsomatic variants

Identifiers

PMID35441233
PMCPMC9612793
OpenAlexW4220914784

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.